Biomarin Pharmaceutical Inc. logo

Biomarin Pharmaceutical Inc. (BMRN)

Market Closed
3 Jun, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
54. 66
+1.34
+2.5131%
Pre Market
$
54. 65
-0.01 -0.0183%
10.64B Market Cap
126.18 P/E Ratio
- Div Yield
1.86M Volume
1 Eps
$ 53.32
Previous Close
Add Transaction
Day Range
53.01 55
Year Range
49.26 66.28
Want to track BMRN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
BioMarin Pharmaceuticals: Share Downdraft Combined With VOXZOGO Potential Makes A Buy

BioMarin Pharmaceuticals: Share Downdraft Combined With VOXZOGO Potential Makes A Buy

BioMarin's stock has dropped over 26% since July 2024, raising questions about whether it's a bargain or a falling knife. Key issues include valuation, stock volatility, an underwhelming investor's day, and competition with their drug VOXZOGO. The sharp decline in share price invites a reassessment of BioMarin's current investment prospects.

Seekingalpha | 1 year ago
Here is Why Growth Investors Should Buy BioMarin (BMRN) Now

Here is Why Growth Investors Should Buy BioMarin (BMRN) Now

BioMarin (BMRN) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks | 1 year ago
5 Biotech Stocks Worth Adding to Your Portfolio in 2025

5 Biotech Stocks Worth Adding to Your Portfolio in 2025

New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry despite the uncertain macro environment. A strong portfolio and solid pipeline progress position INCY, BMRN, EXEL, HALO and BPMC well in this volatile sector.

Zacks | 1 year ago
Wall Street Analysts Predict a 45.86% Upside in BioMarin (BMRN): Here's What You Should Know

Wall Street Analysts Predict a 45.86% Upside in BioMarin (BMRN): Here's What You Should Know

The consensus price target hints at a 45.9% upside potential for BioMarin (BMRN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks | 1 year ago
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 1 year ago
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks | 1 year ago
3 Reasons Why Growth Investors Shouldn't Overlook BioMarin (BMRN)

3 Reasons Why Growth Investors Shouldn't Overlook BioMarin (BMRN)

BioMarin (BMRN) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks | 1 year ago
BMRN or TECH: Which Is the Better Value Stock Right Now?

BMRN or TECH: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either BioMarin Pharmaceutical (BMRN) or Techne (TECH). But which of these two stocks presents investors with the better value opportunity right now?

Zacks | 1 year ago
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term

Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks | 1 year ago
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term

Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks | 1 year ago
Is the Options Market Predicting a Spike in BioMarin Pharmaceutical (BMRN) Stock?

Is the Options Market Predicting a Spike in BioMarin Pharmaceutical (BMRN) Stock?

Investors need to pay close attention to BioMarin Pharmaceutical (BMRN) stock based on the movements in the options market lately.

Zacks | 1 year ago
BioMarin Pharmaceutical (BMRN) is a Top-Ranked Momentum Stock: Should You Buy?

BioMarin Pharmaceutical (BMRN) is a Top-Ranked Momentum Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks | 1 year ago
Loading...
Load More